The combination of idasanutlin with palbociclib, a highly selective inhibitor of CDK4/6 widely used in clinical trials, was reported to wield great antitumor properties in dedifferentiated liposarcomas when compared to monotherapy [88]. The gene discussed is CDK4; the disease is liposarcoma.